The Stockholm-based rare disease specialist Wilson Therapeutics AB has appointed Hans Schikan to its board of directors. Mr Schikan was recently the chief executive of Prosensa, a Dutch company focused on RNA-modulating therapeutics for the treatment of genetic disorders. Prosensa was acquired by BioMarin Pharmaceutical Inc in November 2014. Mr Schikan is also a member of the boards of Swedish Orphan Biovitrum AB and Hansa Medical AB. He trained as a pharmacist at Utrecht University in the Netherlands.
Wilson Therapeutics announced the appointment on 2 July 2015.
Copyright 2015 Evernow Publishing Ltd